THIOTEPA
| Brand name | TEPADINA AND SODIUM CHLORIDE |
|---|---|
| Active ingredient | THIOTEPA |
| Strength | 200MG |
| Dosage form | POWDER |
| Route | INTRAVENOUS |
| Modality | Small molecule |
| FDA approval | April 2025 |
| Marketing status | RX |
| Patent | Expires | Type |
|---|---|---|
| 9931458 | May 2037 | product |
Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.